Braslyn’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Braslyn’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,135,966	Closed	-$184M	–	3
2023 Q4	$184M	Buy	+3,135,966	New	+$176M	98.96%	1

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Braslyn's MRTX Position: Q1 2024 in Review

Braslyn sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 3,135,966 shares — an estimated $184M sold.

Braslyn first reported a position in MRTX in Q4 2023 and held it in 1 quarter. The position peaked at $184M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Braslyn reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Braslyn sold 3,135,966 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $184M.
Braslyn first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
Braslyn's Mirati Therapeutics, Inc. Common Stock position peaked at $184M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Braslyn's 13F filing for Q1 2024, filed 15 May 2024.